Warming Moxibustion Relieves Chronic Visceral Hyperalgesia in Rats: Relations to Spinal Dynorphin and Orphanin-FQ System

Figure 2

(a) AWR was used for behavioral assessment to evaluation effects of i.t. dynorphinA (1-17) or/and 𝜅 receptor antagonist on CVH at different levels of CRD stimuli (2.66, 5.32, 7.98, and 10.64 kPa). Data are presented as the mean ± SEM (𝑛=6 per group). **𝑃<0.01 versus normal group; ^##𝑃<0.01, ^#𝑃<0.05 versus model group; ^▴▴𝑃<0.01, ^▴𝑃<0.05 versus DYN group. DYN: dynorphinA (1-17), nor-BNI: 𝜅 antagonist nor-binaltorphimine. (b) AWR was used for behavioral assessment to evaluation effects of i.t. dynorphinA (1-17) or/and 𝜅 receptor antagonist on moxibustion analgesia at different levels of CRD stimuli (2.66, 5.32, 7.98, and 10.64 kPa). Data are presented as the mean ± SEM (𝑛=6 per group). **𝑃<0.01 versus normal group; ^##𝑃<0.01 versus model group; ^▴▴𝑃<0.01, ^▴𝑃<0.05 versus WM group. DYN: dynorphinA (1-17), nor-BNI: 𝜅 antagonist nor-binaltorphimine, WM: warming moxibustion.

(a)

(b)